Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive

This study has been completed.
Information provided by:
Duramed Research Identifier:
First received: September 12, 2005
Last updated: February 4, 2010
Last verified: February 2010
This is an open-label, single treatment study. All subjects will receive one year of oral contraceptive therapy with DR-1011. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.

Condition Intervention Phase
Drug: DR-1011
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose, Combination Oral Contraceptive, Which Utilizes Ethinyl Estradiol During the Seven Day Interval Between Each 84-day Cycle

Resource links provided by NLM:

Further study details as provided by Duramed Research:

Primary Outcome Measures:
  • Pregnancy Rate (Pearl Index) [ Time Frame: After the onset of treatment and within 14 days after the last combination pill (approx. 1 year of treatment) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adverse Events Reported by Patients and Investigators [ Time Frame: Up to one year ] [ Designated as safety issue: Yes ]

Enrollment: 2235
Study Start Date: June 2005
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Investigational Drug
Drug: DR-1011
1 tablet daily
Other Name: levonorgestrel/ethinyl estradiol


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Premenopausal
  • Not pregnant or breastfeeding
  • Sexually active at risk of pregnancy

Exclusion Criteria:

  • Any contraindication to the use of oral contraceptives
  • Pregnancy within the last 3 months
  • Smoking > 10 cigarettes per day
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00196326

  Show 55 Study Locations
Sponsors and Collaborators
Duramed Research
Study Chair: Duramed Protocol Chair Duramed Research, Inc.
  More Information

Responsible Party: Druamed Protocol Chair, Duramed Research, Inc. Identifier: NCT00196326     History of Changes
Other Study ID Numbers: DR-PSE-309 
Study First Received: September 12, 2005
Results First Received: November 21, 2008
Last Updated: February 4, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Duramed Research:
pregnancy prevention
oral contraceptives

Additional relevant MeSH terms:
Polyestradiol phosphate
Ethinyl Estradiol
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol valerate
Contraceptive Agents
Contraceptives, Oral
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Reproductive Control Agents
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic processed this record on September 29, 2016